Full-Time

Lead – Patent Agent

Posted on 8/15/2024

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

51-200 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Must reside and work within the United States in a state where Amylyx currently does business.

Category
Intellectual Property (IP)
Legal & Compliance
Requirements
  • Must be a registered patent agent in good standing with United States Patent and Trademark Office
  • Ph.D. in chemistry, biochemistry, or other life-science related field, or M.S. with relevant technical life-science industry experience
  • 5+ years patent prosecution experience with significant expertise in drafting and prosecuting patents related to small-molecule pharmaceuticals
  • Expertise in conducting patentability and patent freedom-to-operate searches and analyses on small molecule therapeutics
  • Experience managing high-volume global patent docket
  • Effective and proactive communicator
Responsibilities
  • Draft and prosecute patent applications and manage day-to-day patent prosecution activities and deadlines, including drafting office action responses, formal documents, and other filings
  • Partner with external patent counsel toward cost-effective management of global patent prosecution activities in strategic alignment with business priorities and goals
  • Proactively track R&D, clinical, and manufacturing activities toward invention harvesting and developing patent strategy to protect Amylyx technology
  • Proactively track and review publication activity and public disclosures to ensure alignment with patent strategy
  • Perform patentability, freedom-to-operate, and patent due diligence analyses
  • Develop and implement internal processes toward cost-effective management of global patent portfolio
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials, including the CENTAUR ALS trial, which showed significant benefits for ALS patients through a randomized, double-blind, placebo-controlled study. They are also conducting the PEGASUS trial to assess AMX0035's safety and effectiveness for Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-13%

1 year growth

5%

2 year growth

8%
Simplify Jobs

Simplify's Take

What believers are saying

  • Positive CENTAUR trial results boost AMX0035's credibility for ALS treatment.
  • Growing interest in combination therapies aligns with Amylyx's AMX0035 strategy.
  • FDA's expedited approval initiatives could accelerate Amylyx's drug pipeline.

What critics are saying

  • Relyvrio's Phase III trial failure impacts Amylyx's reputation and future approvals.
  • Avexitide acquisition may strain finances if Phase 3 trials underperform.
  • New CCO Dan Monahan might disrupt operations with strategic shifts.

What makes Amylyx Pharmaceuticals unique

  • Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's, unlike many competitors.
  • AMX0035 combines sodium phenylbutyrate and taurursodiol, a unique approach in treatment.
  • Amylyx engages in community awareness campaigns, enhancing its brand and patient support.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

INACTIVE